ערך בספרים למניה: Anew Medical (WENA)

Anew Medical, Inc. (WENA) is developing Klotho protein-based gene therapies to combat ALS and Alzheimer's. The net asset value per share demonstrates the capitalization, with the -0.10 mark characterizing this parameter. Operations are strictly regulated by FDA standards regarding the disposal of biomaterials. The development of new drugs relies on close collaboration with academic research laboratories.

Book value per share reflects the net value of the company's assets minus its liabilities, allowing a book value per share chart to assess the actual tangible support for each security. This metric, calculated as the ratio of equity to the number of shares, confirms the financial stability of Anew Medical, Inc. (WENA) amid the capitalization of intellectual property rights for gene therapy targeting neurodegenerative diseases.